Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Evolut PRO Kiinan kliininen tutkimus

torstai 29. lokakuuta 2026 päivittänyt: Medtronic Cardiovascular

Medtronic CoreValve™ Evolut™ PRO -järjestelmän Kiinan kliininen tutkimus

Interventional study to evaluate the safety and efficacy of the Medtronic CoreValve™ Evolut™ PRO System when used by China implanting centers in Chinese patients with severe symptomatic aortic stenosis (AS) who are at high risk for Surgical Aortic Valve Replacement (SAVR).

Tutkimuksen yleiskatsaus

Tila

Aktiivinen, ei rekrytointi

Yksityiskohtainen kuvaus

The study is targeting 6 centers with a maximum of 8 centers in China and estimating 65 subjects with a maximum of up to 70 subjects with attempted implants including 50 subjects with an attempted implant in primary study population and the first two attempted subjects at each site for roll-in population. The subjects will follow the assessment with pre and post-procedure, discharge, 30 days(primary endpoint), 6 months, 1 year, and annually through 5 years.

Opintotyyppi

Interventio

Ilmoittautuminen (Todellinen)

52

Vaihe

  • Ei sovellettavissa

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

    • Beijing Municipality
      • Beijing, Beijing Municipality, Kiina, 100000
        • Chinese PLA General Hospital, Chinese PLA Medical School
      • Beijing, Beijing Municipality, Kiina, 100000
        • Beijing Anzhen Hospital, Capital Medical University
    • Sichuan
      • Chengdu, Sichuan, Kiina, 610000
        • West China Hospital of Sichuan University
    • Zhejiang
      • Hangzhou, Zhejiang, Kiina, 310009
        • The Second Affiliated Hospital Zhejiang University School of Medicine

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

65 vuotta ja vanhemmat (Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  1. Aortic valve area (AVA) < 1.0 cm2 (or indexed AVA <0.6 cm2/m2) OR mean gradient > 40 mmHg, OR max aortic velocity > 4.0 m/sec
  2. High risk for SAVR defined as STS-PROM score ≥ 8% AND ≤ 15%, OR documented Heart Team agreement of high risk for AVR due to frailty or comorbidities
  3. Symptoms of aortic stenosis and NYHA ≥ II

Exclusion Criteria:

  1. Age is less than 65 years old
  2. Non-calcified aortic valve
  3. Bicuspid aortic valve with no raphe or 2 raphes (Sievers classification type 0 or type 2)
  4. Ascending aortic diameter > 4.5 cm

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Ei käytössä
  • Inventiomalli: Yksittäinen ryhmätehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Medtronic CoreValve™ Evolut™ PRO System

The system comprised of the following three components:

  1. CoreValve™ Evolut™ PRO Transcatheter Aortic Valve (TAV)
  2. EnVeo™ PRO Delivery Catheter System (DCS)
  3. EnVeo™ PRO Loading System (LS)

The system comprised of the following three components:

  1. CoreValve™ Evolut™ PRO Transcatheter Aortic Valve (TAV)
  2. EnVeo™ PRO Delivery Catheter System (DCS)
  3. EnVeo™ PRO Loading System (LS)

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
All-cause Mortality
Aikaikkuna: 30 days

All-cause mortality at 30 days

30 days
Percentage (%) of Subjects With Evaluable Echocardiograms With Moderate or Severe Aortic Regurgitation by Transthoracic Echocardiography (TTE)
Aikaikkuna: 30 days

Percentage (%) of Subjects with evaluable echocardiograms with moderate or severe aortic regurgitation by transthoracic echocardiography (TTE)

30 days

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Incidence of an VARC II Combined Composite
Aikaikkuna: 30 days

Incidence of an VARC II combined composite includes the following components:

  • All-cause mortality
  • All stroke (disabling and non-disabling)
  • Life-threatening bleeding
  • Acute kidney injury: stage 2 or 3 (including renal replacement therapy)
  • Coronary artery obstruction requiring intervention
  • Major vascular complication
  • Valve-related dysfunction requiring repeat procedure (BAV, TAVI, or SAVR)
30 days
Event Rates of the Individual Components of the VARC II Composite
Aikaikkuna: 30 days

Event rate of the individual components listed in the outcome

30 days
New Permanent Pacemaker Rate
Aikaikkuna: 30 days

New permanent pacemaker rate

30 days
Device Success Rate
Aikaikkuna: Between 24 hours and 7 days post procedure

Device success rate:

  • Percentage of participants with absence of procedural mortality, AND
  • Percentage of participants with correct positioning of a single prosthetic heart valve into the proper anatomical location, AND
  • Percentage of participants with intended performance of the prosthetic heart valve, defined as the absence of patient-prosthesis-mismatch and mean aortic valve gradient less than 20 mmHg (or peak velocity <3m/sec), AND absence of moderate or severe prosthetic valve regurgitation
Between 24 hours and 7 days post procedure
Valve Performance Parameter - Mean Aortic Gradient
Aikaikkuna: 30 days

Mean aortic gradient

30 days
Valve Performance Parameter - Effective Orifice Area
Aikaikkuna: 30 days

Effective orifice area

30 days
Valve Performance Parameter -Degree of Aortic Regurgitation (Transvalvular, Paravalvular, Total)
Aikaikkuna: 30 days

Degree of aortic regurgitation (transvalvular, paravalvular, total)

30 days

Muut tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Event Rates of TAVI-related Complications
Aikaikkuna: 30 days

Rate of the following TAVI-related complications:

  1. change to surgery
  2. need for cardiopulmonary mechanical assistance
  3. coronary occlusion or obstruction
  4. annular rupture or dissection
  5. ventricular perforation
  6. mitral valve damage
  7. prosthetic valve displacement, migration, or embolism
  8. acute kidney injury (up to 7 days post procedure)
30 days
All-cause Mortality
Aikaikkuna: 6 months

Percentage of participants with all-cause mortality

6 months
All-cause Mortality
Aikaikkuna: 1 year

Percentage of participants with all-cause mortality

1 year
All Stroke
Aikaikkuna: 6 months

Incidence of stroke (disabling and non-disabling)

6 months
All Stroke
Aikaikkuna: 1 year

Incidence of stroke (disabling and non-disabling)

1 year
Myocardial Infarction
Aikaikkuna: 30 days

Incidence of MI

30 days
Myocardial Infarction
Aikaikkuna: 6 months

Incidence of MI

6 months
Myocardial Infarction
Aikaikkuna: 1 Year

Incidence of MI

1 Year
Incidence of Life-threatening Bleeding
Aikaikkuna: 30 days

Incidence of life-threatening bleeding:

  1. Fatal bleeding (BARC type 5) OR
  2. Bleeding in a critical organ, such as intracranial, intraspinal, intraocular, or pericardial necessitating pericardiocentesis, or intramuscular with compartment syndrome (BARC type 3b and 3c) OR
  3. Bleeding causing hypovolemic shock or severe hypotension requiring vasopressors or surgery (BARC type 3b) OR
  4. Overt source of bleeding with drop in hemoglobin ≥5 g/dL or whole blood or packed red blood cells (RBCs) transfusion ≥4 units* (BARC type 3b)
30 days
Incidence of Life-threatening Bleeding
Aikaikkuna: 6 months

Incidence of life-threatening bleeding:

  1. Fatal bleeding (BARC type 5) OR
  2. Bleeding in a critical organ, such as intracranial, intraspinal, intraocular, or pericardial necessitating pericardiocentesis, or intramuscular with compartment syndrome (BARC type 3b and 3c) OR
  3. Bleeding causing hypovolemic shock or severe hypotension requiring vasopressors or surgery (BARC type 3b) OR
  4. Overt source of bleeding with drop in hemoglobin ≥5 g/dL or whole blood or packed red blood cells (RBCs) transfusion ≥4 units* (BARC type 3b)
6 months
Incidence of Life-threatening Bleeding
Aikaikkuna: 1 Year

Incidence of life-threatening bleeding:

  1. Fatal bleeding (BARC type 5) OR
  2. Bleeding in a critical organ, such as intracranial, intraspinal, intraocular, or pericardial necessitating pericardiocentesis, or intramuscular with compartment syndrome (BARC type 3b and 3c) OR
  3. Bleeding causing hypovolemic shock or severe hypotension requiring vasopressors or surgery (BARC type 3b) OR
  4. Overt source of bleeding with drop in hemoglobin ≥5 g/dL or whole blood or packed red blood cells (RBCs) transfusion ≥4 units* (BARC type 3b)
1 Year
New AV-Conduction Disturbances (Left Bundle Branch Block (LBBB) and Right Bundle Branch Block (RBBB))
Aikaikkuna: 30 days

Incidence of either LBBB or RBBB

30 days
Incidence of Prosthetic Valve Endocarditis
Aikaikkuna: 30 days

Incidence of prosthetic valve endocarditis:

Any one of the following:

  1. Fulfillment of the following Duke criteria for definite endocarditis

    • Histologic and/or microbiologic evidence of infection at surgery or autopsy, or
    • 2 major criteria, or
    • 1 major criteria and 3 minor criteria, or
    • 5 minor criteria
  2. Evidence of abscess, paravalvular leak, pus, or vegetation confirmed as secondary to infection by histological or bacteriological studies during a re-operation

  3. Findings of abscess, pus, or vegetation involving the CoreValve™ Evolut™ PRO at autopsy

30 days
Incidence of Prosthetic Valve Endocarditis
Aikaikkuna: 6 months

Incidence of prosthetic valve endocarditis:

Any one of the following:

  1. Fulfillment of the following Duke criteria for definite endocarditis

    • Histologic and/or microbiologic evidence of infection at surgery or autopsy, or
    • 2 major criteria, or
    • 1 major criteria and 3 minor criteria, or
    • 5 minor criteria
  2. Evidence of abscess, paravalvular leak, pus, or vegetation confirmed as secondary to infection by histological or bacteriological studies during a re-operation

  3. Findings of abscess, pus, or vegetation involving the CoreValve™ Evolut™ PRO at autopsy

6 months
Incidence of Prosthetic Valve Endocarditis
Aikaikkuna: 1 Year

Incidence of prosthetic valve endocarditis:

Any one of the following:

  1. Fulfillment of the following Duke criteria for definite endocarditis

    • Histologic and/or microbiologic evidence of infection at surgery or autopsy, or
    • 2 major criteria, or
    • 1 major criteria and 3 minor criteria, or
    • 5 minor criteria
  2. Evidence of abscess, paravalvular leak, pus, or vegetation confirmed as secondary to infection by histological or bacteriological studies during a re-operation

  3. Findings of abscess, pus, or vegetation involving the CoreValve™ Evolut™ PRO at autopsy

1 Year
Incidence of Prosthetic Valve Thrombosis
Aikaikkuna: 30 days

Incidence of Prosthetic valve thrombosis:

Any thrombus attached to or near an implanted valve that occludes part of the blood flow path, interferes with valve function, or is sufficiently large to warrant treatment.

*Valve-associated thrombus identified at autopsy in a patient whose cause of death was not valve related should not be reported as valve thrombosis.

30 days
Incidence of Prosthetic Valve Thrombosis
Aikaikkuna: 6 months

Incidence of Prosthetic valve thrombosis:

Any thrombus attached to or near an implanted valve that occludes part of the blood flow path, interferes with valve function, or is sufficiently large to warrant treatment.

*Valve-associated thrombus identified at autopsy in a patient whose cause of death was not valve related should not be reported as valve thrombosis.

6 months
Incidence of Prosthetic Valve Thrombosis
Aikaikkuna: 1 Year

Incidence of Prosthetic valve thrombosis:

Any thrombus attached to or near an implanted valve that occludes part of the blood flow path, interferes with valve function, or is sufficiently large to warrant treatment.

*Valve-associated thrombus identified at autopsy in a patient whose cause of death was not valve related should not be reported as valve thrombosis.

1 Year
Valve-related Dysfunction
Aikaikkuna: 1 Year

Incidence of valve-related dysfunction defined as moderate or severe prosthetic valve stenosis, or moderate or severe prosthetic regurgitation (per VARC II)

1 Year
Incidence of Valve-related Dysfunction Requiring Repeat Procedure
Aikaikkuna: 30 days

Incidence of Valve-related dysfunction requiring repeat procedure

30 days
Incidence of Valve-related Dysfunction Requiring Repeat Procedure
Aikaikkuna: 6 months

Incidence of Valve-related dysfunction requiring repeat procedure

6 months
Incidence of Valve-related Dysfunction Requiring Repeat Procedure
Aikaikkuna: 1 Year

Incidence of Valve-related dysfunction requiring repeat procedure

1 Year
Valve Hemodynamic Performance Metric - Mean Aortic Gradient
Aikaikkuna: 1 year

Mean aortic gradient

1 year
Valve Hemodynamic Performance Metric - Effective Orifice Area
Aikaikkuna: 1 year

Effective orifice area

1 year
Valve Hemodynamic Performance Metric - Degree of Aortic Regurgitation (Transvalvular, Paravalvular, Total)
Aikaikkuna: 1 year

Degree of aortic regurgitation (transvalvular, paravalvular, total)

1 year
New York Heart Association (NYHA) Functional Classification
Aikaikkuna: 30 days

New York Heart Association (NYHA) functional classification system is a tool that classifies patients with heart failure into one of four classes according to their degree of systems at rest and with activity. Below are the four classes and the associated patient symptoms (i.e., Class I has no limitations of physical activity vs. Class IV is most symptomatic and patient has symptoms of heart failure at rest).

Class I: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath.

Class II: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain.

Class III: Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain.

Class IV: Symptoms of heart failure at rest. Any physical activity causes further discomfort.

30 days
New York Heart Association (NYHA) Functional Classification
Aikaikkuna: 6 month

New York Heart Association (NYHA) functional classification system is a tool that classifies patients with heart failure into one of four classes according to their degree of systems at rest and with activity. Below are the four classes and the associated patient symptoms (i.e., Class I has no limitations of physical activity vs. Class IV is most symptomatic and patient has symptoms of heart failure at rest).

Class I: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath.

Class II: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain.

Class III: Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain.

Class IV: Symptoms of heart failure at rest. Any physical activity causes further discomfort.

6 month
New York Heart Association (NYHA) Functional Classification
Aikaikkuna: 1 Year

New York Heart Association (NYHA) functional classification system is a tool that classifies patients with heart failure into one of four classes according to their degree of systems at rest and with activity. Below are the four classes and the associated patient symptoms (i.e., Class I has no limitations of physical activity vs. Class IV is most symptomatic and patient has symptoms of heart failure at rest).

Class I: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath.

Class II: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain.

Class III: Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain.

Class IV: Symptoms of heart failure at rest. Any physical activity causes further discomfort.

1 Year
EQ-5D Quality of Life
Aikaikkuna: 30 days

EuroQol Group developed this Quality of Life (QOL) questionnaire referred to as EQ-5D that includes a descriptive system comprising five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions.

The answers given to ED-5D can be converted into EQ-5D index and utility scores anchored at 0 for death and 1 for perfect health.

The EQ-5D Index Score is calculated for each study participant and the descriptive statistical summary of the EQ-5D score for the study population is provided.

The EQ-5D Visual Analog Scale (VAS) Score is a scale numbered 0 to 100 (0 is the worse health the patient can imagine and 100 is the best health the patient can imagine).

30 days
EQ-5D Quality of Life
Aikaikkuna: 1 Year

EuroQol Group developed this Quality of Life (QOL) questionnaire referred to as EQ-5D that includes a descriptive system comprising five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions.

The answers given to ED-5D can be converted into EQ-5D index and utility scores anchored at 0 for death and 1 for perfect health.

The EQ-5D Index Score is calculated for each study participant and the descriptive statistical summary of the EQ-5D score for the study population is provided.

The EQ-5D Visual Analog Scale (VAS) Score is a scale numbered 0 to 100 (0 is the worse health the patient can imagine and 100 is the best health the patient can imagine).

1 Year
All-cause Mortality
Aikaikkuna: 2 year

Percentage of participants with all-cause mortality

2 year
All Stroke
Aikaikkuna: 2 year

Incidence of stroke (disabling and non-disabling)

2 year
Myocardial Infarction
Aikaikkuna: 2 Year

Incidence of MI

2 Year
Incidence of Life-threatening Bleeding
Aikaikkuna: 2 Year

Incidence of life-threatening bleeding:

  1. Fatal bleeding (BARC type 5) OR
  2. Bleeding in a critical organ, such as intracranial, intraspinal, intraocular, or pericardial necessitating pericardiocentesis, or intramuscular with compartment syndrome (BARC type 3b and 3c) OR
  3. Bleeding causing hypovolemic shock or severe hypotension requiring vasopressors or surgery (BARC type 3b) OR
  4. Overt source of bleeding with drop in hemoglobin ≥5 g/dL or whole blood or packed red blood cells (RBCs) transfusion ≥4 units* (BARC type 3b)
2 Year
Incidence of Prosthetic Valve Endocarditis
Aikaikkuna: 2 Year

Incidence of prosthetic valve endocarditis:

Any one of the following:

  1. Fulfillment of the following Duke criteria for definite endocarditis

    • Histologic and/or microbiologic evidence of infection at surgery or autopsy, or
    • 2 major criteria, or
    • 1 major criteria and 3 minor criteria, or
    • 5 minor criteria
  2. Evidence of abscess, paravalvular leak, pus, or vegetation confirmed as secondary to infection by histological or bacteriological studies during a re-operation

  3. Findings of abscess, pus, or vegetation involving the CoreValve™ Evolut™ PRO at autopsy

2 Year
Incidence of Prosthetic Valve Thrombosis
Aikaikkuna: 2 Year

Incidence of Prosthetic valve thrombosis:

Any thrombus attached to or near an implanted valve that occludes part of the blood flow path, interferes with valve function, or is sufficiently large to warrant treatment.

*Valve-associated thrombus identified at autopsy in a patient whose cause of death was not valve related should not be reported as valve thrombosis.

2 Year
Valve-related Dysfunction
Aikaikkuna: 2 Year

Incidence of valve-related dysfunction defined as moderate or severe prosthetic valve stenosis, or moderate or severe prosthetic regurgitation (per VARC II)

2 Year
Incidence of Valve-related Dysfunction Requiring Repeat Procedure
Aikaikkuna: 2 Year

Incidence of Valve-related dysfunction requiring repeat procedure

2 Year
Valve Hemodynamic Performance Metric - Mean Aortic Gradient
Aikaikkuna: 2 year

Mean aortic gradient

2 year
Valve Hemodynamic Performance Metric - Effective Orifice Area
Aikaikkuna: 2 year

Effective orifice area

2 year
Valve Hemodynamic Performance Metric - Degree of Aortic Regurgitation (Transvalvular, Paravalvular, Total)
Aikaikkuna: 2 year

Degree of aortic regurgitation (transvalvular, paravalvular, total)

2 year
New York Heart Association (NYHA) Functional Classification
Aikaikkuna: 2 Year

New York Heart Association (NYHA) functional classification system is a tool that classifies patients with heart failure into one of four classes according to their degree of systems at rest and with activity. Below are the four classes and the associated patient symptoms (i.e., Class I has no limitations of physical activity vs. Class IV is most symptomatic and patient has symptoms of heart failure at rest).

Class I: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath.

Class II: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain.

Class III: Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain.

Class IV: Symptoms of heart failure at rest. Any physical activity causes further discomfort.

2 Year
All-cause Mortality
Aikaikkuna: 3 year

Percentage of participants with all-cause mortality

3 year
All Stroke
Aikaikkuna: 3 year

Incidence of stroke (disabling and non-disabling)

3 year
Myocardial Infarction
Aikaikkuna: 3 Year

Incidence of MI

3 Year
Incidence of Life-threatening Bleeding
Aikaikkuna: 3 Year

Incidence of life-threatening bleeding:

  1. Fatal bleeding (BARC type 5) OR
  2. Bleeding in a critical organ, such as intracranial, intraspinal, intraocular, or pericardial necessitating pericardiocentesis, or intramuscular with compartment syndrome (BARC type 3b and 3c) OR
  3. Bleeding causing hypovolemic shock or severe hypotension requiring vasopressors or surgery (BARC type 3b) OR
  4. Overt source of bleeding with drop in hemoglobin ≥5 g/dL or whole blood or packed red blood cells (RBCs) transfusion ≥4 units* (BARC type 3b)
3 Year
Incidence of Prosthetic Valve Endocarditis
Aikaikkuna: 3 Year

Incidence of prosthetic valve endocarditis:

Any one of the following:

  1. Fulfillment of the following Duke criteria for definite endocarditis

    • Histologic and/or microbiologic evidence of infection at surgery or autopsy, or
    • 2 major criteria, or
    • 1 major criteria and 3 minor criteria, or
    • 5 minor criteria
  2. Evidence of abscess, paravalvular leak, pus, or vegetation confirmed as secondary to infection by histological or bacteriological studies during a re-operation

  3. Findings of abscess, pus, or vegetation involving the CoreValve™ Evolut™ PRO at autopsy

3 Year
Incidence of Prosthetic Valve Thrombosis
Aikaikkuna: 3 Year

Incidence of Prosthetic valve thrombosis:

Any thrombus attached to or near an implanted valve that occludes part of the blood flow path, interferes with valve function, or is sufficiently large to warrant treatment.

*Valve-associated thrombus identified at autopsy in a patient whose cause of death was not valve related should not be reported as valve thrombosis.

3 Year
Valve-related Dysfunction
Aikaikkuna: 3 Year

Incidence of valve-related dysfunction defined as moderate or severe prosthetic valve stenosis, or moderate or severe prosthetic regurgitation (per VARC II)

3 Year
Incidence of Valve-related Dysfunction Requiring Repeat Procedure
Aikaikkuna: 3 Year

Incidence of Valve-related dysfunction requiring repeat procedure

3 Year
Valve Hemodynamic Performance Metric - Mean Aortic Gradient
Aikaikkuna: 3 year

Mean aortic gradient

3 year
Valve Hemodynamic Performance Metric - Effective Orifice Area
Aikaikkuna: 3 year

Effective orifice area

3 year
Valve Hemodynamic Performance Metric - Degree of Aortic Regurgitation (Transvalvular, Paravalvular, Total)
Aikaikkuna: 3 year

Degree of aortic regurgitation (transvalvular, paravalvular, total)

3 year
New York Heart Association (NYHA) Functional Classification
Aikaikkuna: 3 Year

New York Heart Association (NYHA) functional classification system is a tool that classifies patients with heart failure into one of four classes according to their degree of systems at rest and with activity. Below are the four classes and the associated patient symptoms (i.e., Class I has no limitations of physical activity vs. Class IV is most symptomatic and patient has symptoms of heart failure at rest).

Class I: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath.

Class II: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain.

Class III: Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain.

Class IV: Symptoms of heart failure at rest. Any physical activity causes further discomfort.

3 Year

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Tutkijat

  • Päätutkija: Jianan Wang, MD, Second Affiliated Hospital, Zhejiang University, School of Medicine

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Lauantai 17. heinäkuuta 2021

Ensisijainen valmistuminen (Todellinen)

Perjantai 17. maaliskuuta 2023

Opintojen valmistuminen (Arvioitu)

Maanantai 15. toukokuuta 2028

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Torstai 8. heinäkuuta 2021

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Keskiviikko 28. heinäkuuta 2021

Ensimmäinen Lähetetty (Todellinen)

Torstai 29. heinäkuuta 2021

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Keskiviikko 18. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Torstai 29. lokakuuta 2026

Viimeksi vahvistettu

Torstai 1. lokakuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muut tutkimustunnusnumerot

  • MDT18065EVR009

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa